Jianqing Li

机构：Nanjing University of Chinese Medicine · ORCID：0000-0002-8445-9796

发表论文 108 篇 · 总被引 2377 次 · h-index 27

代表论文

• Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy (2021 · Journal of Medicinal Chemistry · 被引 98)
• Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases (2021 · Journal of Medicinal Chemistry · 被引 60)
• Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design (2021 · Journal of Medicinal Chemistry · 被引 44)
• Discovery of ( S )-1-((2′,6-Bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor in Clinical Trials for the Treatment of Neuropathic Pain (2022 · Journal of Medicinal Chemistry · 被引 33)
• Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4 (2022 · Journal of Medicinal Chemistry · 被引 27)
• Time trends and gender disparities of Chinese cataract burden and their predictions (2023 · International Journal of Ophthalmology · 被引 18)